|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
956,580,000 |
Market
Cap: |
730.81(B) |
Last
Volume: |
1,955,966 |
Avg
Vol: |
3,290,337 |
52
Week Range: |
$423.21 - $792.28 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 720 |
Guru Rank Value : 1.4 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
656 |
Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
220,750 |
870,750 |
2,710,260 |
6,211,418 |
Total Sell Value |
$171,350,547 |
$608,250,580 |
$2,147,483,647 |
$2,147,483,647 |
Total People Sold |
2 |
2 |
5 |
6 |
Total Sell Transactions |
3 |
13 |
42 |
89 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hakim Anat |
SVP, GC & Secretary |
|
2021-03-01 |
4 |
D |
$204.89 |
$715,681 |
D/D |
(3,493) |
4,435 |
|
- |
|
Hakim Anat |
SVP, GC & Secretary |
|
2021-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,928 |
7,928 |
|
- |
|
Tai Jackson P |
Director |
|
2021-02-16 |
4 |
A |
$205.76 |
$2,058 |
D/D |
10 |
59,750 |
|
- |
|
Alvarez Ralph |
Director |
|
2021-02-16 |
4 |
A |
$207.76 |
$11,011 |
D/D |
53 |
49,198 |
|
- |
|
Ashkenazi Anat |
SVP & CFOOfficer |
|
2021-02-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
253 |
|
10% |
|
Ashkenazi Anat |
SVP & CFOOfficer |
|
2021-02-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,700 |
|
10% |
|
Zakrowski Donald A |
Chief Accounting Officer |
|
2021-02-08 |
4 |
A |
$205.77 |
$873,905 |
D/D |
4,247 |
8,987 |
|
- |
|
Yuffa Ilya |
SVP and Pres, Lilly Bio-Meds |
|
2021-02-08 |
4 |
A |
$205.77 |
$727,603 |
D/D |
3,536 |
10,349 |
|
- |
|
Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
|
2021-02-08 |
4 |
A |
$205.77 |
$1,974,157 |
D/D |
9,594 |
34,616 |
|
- |
|
Smiley Joshua L |
Former Officer |
|
2021-02-08 |
4 |
A |
$205.77 |
$5,228,410 |
D/D |
25,409 |
77,659 |
|
- |
|
White Anne E. |
SVP & Pres-Lilly Oncology |
|
2021-02-08 |
4 |
A |
$205.77 |
$970,823 |
D/D |
4,718 |
33,840 |
|
- |
|
Pusey Leigh Ann |
SVP, Corp. Affairs & Comm. |
|
2021-02-08 |
4 |
A |
$205.77 |
$2,220,464 |
D/D |
10,791 |
18,529 |
|
- |
|
Ricks David A |
President & CEO |
|
2021-02-08 |
4 |
A |
$205.77 |
$26,820,679 |
D/D |
130,343 |
440,244 |
|
- |
|
Mason Michael B |
Sr. VP & Pres., Lilly Diabetes |
|
2021-02-08 |
4 |
A |
$205.77 |
$1,306,640 |
D/D |
6,350 |
24,894 |
|
- |
|
Oneill Myles |
SVP & Pres., Mfg. Operations |
|
2021-02-08 |
4 |
A |
$205.77 |
$4,331,870 |
D/D |
21,052 |
72,533 |
|
- |
|
Zulueta Alfonso G |
SVP & President, Lilly Intl |
|
2021-02-08 |
4 |
A |
$205.77 |
$5,974,943 |
D/D |
29,037 |
56,947 |
|
- |
|
Skovronsky Daniel |
SVP, CSO, and Pres. LRL |
|
2021-02-08 |
4 |
A |
$205.77 |
$3,811,066 |
D/D |
18,521 |
115,680 |
|
- |
|
Shah Aarti S. |
SVP & CIDO |
|
2021-02-08 |
4 |
A |
$205.77 |
$2,270,260 |
D/D |
11,033 |
31,622 |
|
- |
|
Norton Johna |
Senior VP, Global Quality |
|
2021-02-08 |
4 |
A |
$205.77 |
$1,242,851 |
D/D |
6,040 |
25,464 |
|
- |
|
Fry Stephen F |
SVP, HR & Diversity |
|
2021-02-08 |
4 |
A |
$205.77 |
$5,377,387 |
D/D |
26,133 |
134,676 |
|
- |
|
Jonsson Patrik |
SVP & President Lilly USA |
|
2021-02-08 |
4 |
A |
$205.77 |
$1,151,283 |
D/D |
5,595 |
30,674 |
|
- |
|
Ashkenazi Anat |
SVP & CFO |
|
2021-02-08 |
4 |
A |
$205.77 |
$1,641,016 |
D/D |
7,975 |
25,675 |
|
- |
|
Smiley Joshua L |
SVP and CFO |
|
2021-02-01 |
4 |
D |
$207.97 |
$1,757,762 |
D/D |
(8,452) |
52,250 |
|
- |
|
Smiley Joshua L |
SVP and CFO |
|
2021-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,266 |
60,702 |
|
- |
|
Zulueta Alfonso G |
SVP & President, Lilly Intl |
|
2021-02-01 |
4 |
D |
$207.97 |
$1,557,695 |
D/D |
(7,490) |
27,910 |
|
- |
|
1437 Records found
|
|
Page 20 of 58 |
|
|